CHRISTINA HALL: Open Payments
NPI 1144819467 · SOMERSET, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$662 in 39 payments from 15 companies in 2025. Trend: 2023 $387 · 2024 $789 · 2025 $662
Food & beverage: $662
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 17 | $152 |
| Merck Sharp & Dohme LLC | 4 | $76 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $60 |
| Celgene Corporation | 2 | $58 |
| Novartis Pharmaceuticals Corporation | 2 | $42 |
| AstraZeneca Pharmaceuticals LP | 2 | $39 |
| E.R. Squibb & Sons, L.L.C. | 2 | $34 |
| Pharmacosmos Therapeutics Inc. | 1 | $34 |
| Gilead Sciences, Inc. | 1 | $30 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $27 |
Products named: QULIPTA, KEYTRUDA, REBLOZYL, AIRSUPRA, FRUZAQLA, MONOFERRIC, UBRELVY, Trodelvy.
Industry payments across KY — which companies pay providers there.
